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hronic Total Occlusion Treated With
rug-Eluting Stents
rancesco De Felice, MD, Rosario Fiorilli, MD, Antonio Parma, MD, Marco Nazzaro, MD,
armine Musto, MD, Fernando Sbraga, MD, Giorgia Caferri, MD, Roberto Violini, MD
ome, Italy
bjectives The aim of this study was to evaluate whether percutaneous coronary intervention (PCI)
ith drug-eluting stent (DES) reduces major adverse cardiac events (MACE) in patients with chronic
oronary total occlusions (CTO) compared with bare-metal stent (BMS) during 3-year follow-up.
ackground The long-term prognosis of patients with CTO treated with PCI and DES implantation
s poorly investigated.
ethods We compared the 3-year clinical outcome of 124 patients with CTO after successful PCI
ith DES implantation with that of 159 patients with CTO previously treated with BMS. MACE were
eﬁned as death, myocardial infarction, and target lesion revascularization (repeat PCI or coronary
rtery bypass surgery) and were considered as combined primary end point.
esults After 3 years, the composite end point was signiﬁcantly lower in the DES than in the BMS
roup: 18% versus 28%, respectively, (p  0.05). The difference was due to the reduction of target
esion revascularization with DES compared with BMS—8% versus 21%, respectively, (p  0.004).
he Cox proportional hazards model identiﬁed: DES versus BMS (adjusted hazard ratio [HR]: 0.338,
5% conﬁdence interval [CI]: 0.19 to 0.60, p  0.0001), lesion length (HR: 1.033, 95% CI: 1.008 to
.058, p  0.012), and ﬁnal minimal lumen diameter (HR: 0.456, 95% CI: 0.232 to 0.898, p  0.023)
s independent predictors of MACE at 3-year follow-up.
onclusions After 3 years, DES were superior to BMS in reducing MACE in patients with CTO and
hould be considered the preferred treatment strategy. (J Am Coll Cardiol Intv 2009;2:1260–5)
2009 by the American College of Cardiology Foundation
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1261uring the past 25 years the use of percutaneous coronary
ntervention (PCI) has become common in the manage-
ent strategy of patients with chronic coronary total occlu-
ion (CTO) (1). Patients with successful recanalization of
TO with PCI have better clinical outcome and improved
eft ventricular function compared with patients in whom
he attempt to re-canalize CTO has failed (2–5). Moreover,
n patients with left anterior descending CTO, successful
CI is associated with improved long-term survival (6). The
See page 1266
igh restenosis rate has limited the benefits of plain old
alloon angioplasty; the implantation of bare-metal stents
BMS) has lowered the rate of repeat target lesion revascu-
arization (TLR). The introduction of sirolimus- (SES) and
aclitaxel-eluting stents (PES) has resulted in a further
mportant reduction of restenosis in patients with CTO (7–10)
ith apparently durable benefits (11). However, data on
ong-term follow-up have shown conflicting results (12,13).
n increased rate of target vessel revascularization (TVR) in
atients with CTO treated with SES has been recently
eported (12). Conversely, a recent randomized study has
hown that the documented superior short-term clinical and
ngiographic results of SES over BMS are maintained during
-year follow-up (13).
The present study aimed to evaluate the 3-year clinical
utcome of successful recanalization with DES implantation
ompared with BMS in patients with CTO.
ethods
tudy population. The study population consisted of 283
onsecutive patients with CTO of native coronary vessels
nd evidence of related myocardial ischemia or viability who
nderwent successful revascularization with implantation of
ES or BMS in our institution. A CTO was defined as a
omplete obstruction of the vessel with Thrombolysis In
yocardial Infarction (TIMI) flow grade 0 and an esti-
ated duration of 3 months. Age of the occlusion was
etermined by the interval from the last episode of acute
oronary syndrome or myocardial infarction consistent with
he location of the occlusion. A successful PCI was defined
s final TIMI flow grade 2 and a residual stenosis 30%
fter stent implantation. Patients with CTO of the left main
oronary artery or of a previously stented coronary artery
ere not included. The DES group included 124 consecu-
ive patients with CTO, who received SES or PES between
anuary 2003 and February 2006. The BMS group included
59 consecutive patients with CTO who had received BMS
n the 4 years preceding the introduction of DES at our
ospital. There was no temporal overlap in the 2 groups
ith regard to stent placement. Only 1 type of stent was
sed in each CTO. The study was conducted in a large- aolume laboratory with more than 1,000 PCIs/year, during
oth BMS and DES time frames. All CTO interventions
ere performed by standard antegrade approach.
All patients were pre-treated with aspirin and either
iclopidine (500 mg/day at least 3 days before the procedure)
r clopidogrel (a loading dose of 300 mg at least 6 h before
he procedure). After the procedure, all patients were given
spirin indefinitely and either ticlopidine 250 mg twice daily
r clopidogrel 75 mg daily for at least 4 weeks after
mplantation of BMS and for at least 3 or 6 months after
mplantation of SES or PES, respectively. Glycoprotein
Ib/IIIa inhibitors were given at the discretion of the
perator.
ngiographic analysis. Angiographic analysis was done on
nd-diastolic frames demonstrating the stenosis on its more
evere view. The view with the least foreshortening was
elected for the analysis. A
omputer-assisted automated al-
orithm (CAAS II, Pie Medical
maging, Maastricht, the Nether-
ands) and standard morphologic
riteria were used for the analysis
f the entire treated segment. Ref-
rence vessel diameter, minimal
umen diameter, and residual ste-
osis percentage were measured.
esion length was measured after
essel recanalization.
nd points. Major adverse car-
iac events (MACE) were de-
ned as death, myocardial infarc-
ion, and TLR and were
onsidered the combined primary
nd point of the study. The sec-
ndary end point was TLR. Myo-
ardial infarction was diagnosed in
he presence of new pathological
waves on electrocardiogram or
rise in creatine kinase (or myocardial band fraction) of more
han twice the upper limit of normal. Target lesion revascu-
arization (TLR) consisted of repeat PCI or coronary artery
ypass surgery due to restenosis or re-occlusion of the target
esion in the presence of objective evidence of ischemia.
ccording to the definitions of the Academic Research Con-
ortium, stent thrombosis (acute: 1 day; subacute: 1 to 30
ays; late: 30 days; very late: 1 year) was categorized as
ollows: 1) “definite” as an acute coronary syndrome with
ngiographic documentation of either occlusion of the target
esion or thrombus within or adjacent to a previously stented
egment; 2) “probable” in case of any unexplained death within
0 days or if a target vessel myocardial infarction occurred
ithout angiographic documentation; and 3) “possible” in case
f any unexplained death after 30 days that could not be
Abbreviations and
Acronyms
BMS  bare-metal stent(s)
CTO  chronic coronary
total occlusion(s)
DES  drug-eluting stent(s)








TIMI  Thrombolysis In
Myocardial Infarction
TLR  target lesion
revascularization
TVR  target vessel
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1262Follow-up protocol included evaluation at hospital dis-
harge and a clinical visit or telephone interview after
ischarge and at 6, 12, 24, and 36 months.
tatistical analysis. We performed a retrospective analysis of
ata that were prospectively collected according to the
rotocol of our institution. Data are presented as mean 
D or percentages. Comparisons between groups were
erformed with t test for continuous data and the chi-square
est or Fisher exact test for categorical data when appropri-
te. Statistical significance was accepted at p  0.05.
The Cox proportional hazards model was used to deter-
ine the independent correlates of the composite primary
nd point of MACE. Logistic regression was performed to
etermine the independent correlates of TLR and TVR.
vent-free survival curves, from MACE and TLR and
VR, were constructed with the Kaplan-Meier method and
ompared with the log-rank test. Analyses were performed
ith the BMDP 2L software package (BMDP Statistical
oftware, Inc., Los Angeles, California).
esults
tudy population. Baseline characteristics are shown in
able 1. Mean age was 62 10 years (range 32 to 85 years);
19 patients were men. Diagnosis of previous myocardial
nfarction had been made in 193 patients, whereas 24
atients had undergone previous revascularization. Among
1 patients with diabetes mellitus, 13 had insulin-requiring
iabetes. The DES group had a statistically significant lower
revalence of previous myocardial infarction in comparison
ith the BMS group.
ngiographic and procedural variables. Angiographic and





(n  159) p Value
Age (yrs) 63 10 61 10 NS
Women 31 (25) 33 (21) NS
Previous myocardial infarction 76 (61) 117 (73) 0.03
Previous coronary artery bypass surgery 4 (3) 3 (2) NS
Previous percutaneous coronary intervention 9 (7) 8 (5) NS
Diabetes NS
Not insulin-requiring 35 (28) 36 (22)
Insulin-requiring 7 (6) 6 (4)
Hypertension 89 (72) 107 (67) NS
Hypercholesterolemia 76 (61) 110 (69) NS
Current smoker 48 (39) 72 (48) NS
Ejection fraction (%) 52 9 52 11 NS
Data are reported as mean  SD or n (%). Hypertension was defined as systolic blood pressure
140 mm Hg, diastolic blood pressure 90 mm Hg, or use of blood pressure-lowering agents.
Hypercholesterolemia was defined as total cholesterol 230 mg/dl or use of a lipid-lowering
agent.
BMS bare-metal stent(s); DES drug-eluting stent(s).rocedural variables are shown in Table 2. Target vessel waseft anterior descending coronary artery in 156 patients,
ircumflex artery in 53 patients, and right coronary artery in
4 patients. Patients with single-vessel disease numbered
59, whereas 124 had multivessel disease. One vessel was
reated in 187 patients, whereas 85 and 11 patients received
reatment of 2 and 3 vessels, respectively. Glycoprotein
Ib/IIIa inhibitors were used in 53 cases. All patients had
nal TIMI flow grade 3, apart from 2 patients in the BMS
roup that had TIMI flow grade 2. Patients treated with
ES (83 patients with SES and 41 patients with PES) had
tatistically significantly longer lesion length and stented
egment length and higher number of stents/lesion than
atients treated with BMS. The BMS group had a larger
aseline reference vessel diameter and a higher final minimal
umen diameter than the DES group.
linical follow-up. With the exception of 17 patients (6
reated with DES, and 11 treated with BMS) who were lost
fter hospital discharge, 266 patients were evaluated after a
ollow-up of 36 months. Clinical events are described in





(n  159) p Value
Target vessel NS
Left anterior descending 67 (54) 89 (56)
Circumﬂex 18 (14) 35 (22)
Right 39 (31) 35 (22)
Treated coronary segment NS
Proximal 43 (35) 54 (34)
Middle 70 (36) 86 (54)
Distal 11 (9) 19 (12)
Number of diseased vessels NS
1 61 (49) 98 (61)
2 51 (41) 52 (33)
3 12 (10) 9 (6)
Number of treated vessels NS
1 74 (60) 113 (71)
2 44 (35) 41 (26)
3 6 (5) 5 (3)
Ostial lesion 2 (1) 2 (1) NS
Bifurcation lesion 6 (5) 6 (4) NS
Glycoprotein IIb/IIIa inhibitor therapy 25 (20) 28 (15) NS
Lesion length (mm) 23 10 16 7 0.0001
Stented segment length (mm) 37 15 21 8 0.0001
Number of stent/lesion 1.6 0.7 1.3 0.6 0.0003
Stent overlapping 62 (50) 45 (39) 0.005
Reference vessel diameter (mm) 2.8 0.3 3.0 0.5 0.001
Final minimal lumen diameter (mm) 2.4 0.3 2.5 0.3 0.0004
Residual stenosis (%) 12 6 11 7 NS
Final TIMI ﬂow grade 3 124 (100) 157 (99) NS
Intravascular ultrasound
examination
6 (5) 5 (3) NS
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1263able 3. At 3-year follow-up, the primary end point of the
tudy occurred in 21 (18%) patients treated with DES and
n 42 (28%) patients treated with BMS (p  0.05). During
he follow-up period, 2 patients in the DES group and 4
atients in the BMS group died from a cardiac etiology,
hereas 4 patients in the DES group and 3 patients in the
MS group suffered myocardial infarction. Patients treated
ith DES underwent a TLR procedure less frequently
ompared with patients treated with BMS—10 (8%) versus
2 (21%), respectively (p  0.004). TVR was performed in
patients in the DES group and in 3 patients in the BMS
roup.
In the DES group 2 patients had myocardial infarction
nd then underwent TLR with PCI. In the BMS group 2
atients had myocardial infarction and then underwent
LR (1 with PCI, and 1 with coronary artery bypass graft).
uring the first year, 4 patients in the DES group and 28
atients in the BMS group had MACE (p  0.0001).
The following variables were entered into the Cox propor-
ional hazards model to determine the independent predictors
f the composite primary end point: type of stent (DES vs.
MS), previous myocardial infarction, diabetes, target vessel,
reated vessel segment, lesion length, stent length, number of
tents/lesion, reference vessel diameter, final minimal lumen
iameter, and residual stenosis percentage. The Cox propor-
ional hazards model identified: type of stent (DES vs. BMS)
adjusted hazard ratio [HR]: 0.338, 95% confidence interval
CI]: 0.19 to 0.60, p 0.0001), lesion length (HR: 1.033, 95%
I: 1.008 to 1.058, p 0.012), final minimal lumen diameter
HR: 0.456, 95% CI: 0.232 to 0.898, p 0.023), and residual
tenosis percentage (HR: 1.031, 95% CI: 0.996 to 1.068, p 
.089) as independent predictors of MACE at 3-year follow-





(n  148) p Value
Long-term events (all) 21 (18) 42 (28) 0.05
Death 7 (6) 7 (5) NS
Cardiac 2 4
Noncardiac 5 3
Myocardial infarction 4 (3) 3 (2) NS
Q-wave 2 2
Non–Q-wave 2 1
TLR 10 (8) 32 (21) 0.004
PCI 8 23
CABG 2 9
TVR (no TLR) 2 (2) 3 (2) NS
PCI 2 3
CABG 0 0
Data are reported as n (%).
CABG coronary artery bypass graft; PCI percutaneous coronary intervention; TLR target
lesion revascularization; TVR target vessel revascularization; other abbreviations as in Table 1.p. To determine the influence of time on the composite endoint, the year of PCI was introduced into the Cox propor-
ional hazards model but was not a predictor of events.
To determine the independent predictors of TLR and
VR, the same aforementioned variables entered into the
ogistic regression model. Stepwise logistic regression analysis
dentified: the type of stent (DES vs. BMS) (odds ratio [OR]:
.29, 95% CI: 0.137 to 0.613, p  0.0011), diabetes (OR:
.99, 95% CI: 0.992 to 3.98, p 0.0496), and residual stenosis
ercentage (OR: 1.08, 95% CI: 0.98 to 1.13, p  0.0014) as
ndependent predictors of TLR and TVR at 3-year follow-up.
The 3-year survival rates free from MACE were 80% in the
ES group and 69.4% in the BMS group (log rank p 0.025)
Fig. 1). The 3-year survival rates free from TLR and TVR
ere 88.4% in the DES group and 74.4% in the BMS group
log rank p 0.044) (Fig. 2). A DES implantation resulted in
reduction of 36% in MACE and of 62% in TLR compared
ith BMS.
tent thrombosis. Definite very late thrombosis occurred in 4
atients in the DES group at 27, 31, and 33 (2 cases) months,
espectively. Definite late thrombosis occurred in 3 patients in
he BMS group at 1, 6, and 8 months, respectively. Definite
ub-acute thrombosis occurred in 1 patient in the BMS group.
robable late thrombosis occurred in 1 patient in the DES
roup and in 1 patient in the BMS group (p  NS).
iscussion
he present study demonstrates that in patients with CTO: 1)
he benefits of DES compared with BMS with regard to
ACE, demonstrated at 1 year, are maintained up to 3-year
ollow-up; and 2) type of stent, stenosis length, and final
inimal luminal diameter are predictors of MACE after 3
ears of follow-up.
Patients with CTO represent a very high risk group for PCI.
alloon angioplasty of CTO is limited by frequent acute vessel
Figure 1. Event-Free From MACE Survival Curves
Event-free survival curves for drug-eluting stents (DES) and bare-metal
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1264e-occlusion and high rates of restenosis. Stent implantation
as almost abolished the occurrence of abrupt vessel closure,
ut its impact on restenosis reduction has been less pronounced
4,5). Recently, both SES and PES have been shown to be safe
nd effective, and they have markedly reduced the incidence of
estenosis and need for TLR in patients with CTO (6–10).
owever, poor, incomplete, and conflicting data are available
bout long-term follow-up in patients with CTO treated with
ES (12,13).
We compared the long-term clinical outcome of 124 pa-
ients with CTO after successful PCI with DES implantation
both SES and PES) with that of 159 patients with CTO
reviously treated with BMS. We found that the incidence of
ACE was markedly reduced among patients with CTO
reated with DES as compared with BMS after 3-year follow-
p. The benefit was due to the reduction of TLR. This finding
onfirms that the beneficial effect of DES in CTO is achieved
hrough a reduction of restenosis and TVR (5–9) and is
aintained for the long term.
Our data are not in line with Garcia-Garcia et al. (12). They
howed that, despite clinical and angiographic benefits at 1
ear, the use of SES was no longer associated with significantly
ower rates of TLR and MACE in patients with CTO in
omparison with BMS. Different factors might have influ-
nced the high number of MACE in the DES group of the
tudy by Garcia-Garcia et al. (12): 1) because mean stent
iameter was lower in the DES group and reference vessel
iameter was not provided, it is not possible to exclude that
ES had been undersized; and 2) because lesion length was
ot available and stent length was not different between the
roups, we cannot exclude that the length of implanted DES
ad been under-evaluated. Generally, 2 factors might hypo-
hetically explain the absence of prolonged benefits of DES: a
ate catch-up phenomenon, and/or late stent thrombosis. The
Figure 2. Event-Free From TVR and TLR Survival Curves
Event-free survival curves for DES and BMS. TLR  target lesion revasculariza-
tion; TVR  target vessel revascularization; other abbreviations as in Figure 1.rst is a significant luminal deterioration during late follow-up fescribed in porcine models after DES implantation (16).
owever, observations 5 years after SES implantation (17) and
fter 2 years with PES in complex lesions (18) seem to indicate
he absence of late catch-up phenomenon of DES. In our
tudy, patients with CTO treated with DES had no statisti-
ally significant difference in repeat TLR after 1 year with
espect to the BMS group. Given these data the presence of a
ate catch-up phenomenon with DES seems to be unlikely
ven in patients with very complex lesions as CTO. Late
hrombosis is currently under evaluation as a potential factor
ffecting the long-term safety of DES. Although the possibility
f an augmented stent thrombosis after DES implantation has
een reported, a recent and large meta-analysis did not show an
ncreased risk of definite stent thrombosis after SES as com-
ared with BMS (19). We did not find statistically significant
ifferences in stent thrombosis between the groups of patients
ith CTO treated with or without DES. Moreover, the
uperiority of DES over BMS in reducing MACE was
btained without an increase of death or myocardial infarction
ttributable to stent thrombosis. Unfortunately the safety of
ES in the setting of CTOs has not yet been resolved. The
umber of patients included in the present study was not large
nough to extrapolate definite conclusions about this issue.
lthough the low rate of stent thrombosis in the present study
ight seem reassuring, larger dedicated studies are needed to
nswer this question definitively. Furthermore, the role of
ong-term dual antiplatelet therapy in patients with CTO
reated with DES remains to be defined.
Our results are in agreement with the data of a recent
andomized trial (PRISON II [Primary Stenting of Totally
ccluded Native Coronary Arteries II]), which shows the
uperiority of DES over BMS in patients with CTO (13).
owever, some main differences between the studies should be
emarked upon. The present study is not randomized—
iffering from the PRISON II study—but reflects the out-
omes of a real-world population: our patients treated with
ES had less-favorable characteristics, including longer occlu-
ions and stented lengths, traditionally recognized as predictors
f an increased risk of restenosis. Despite these unfavorable
atterns, the use of DES was associated with significantly
etter clinical outcomes (12). All patients included in the
resent study had a CTO lasting 3 months, whereas only
5% of the patients had a true CTO (3 months) in the
RISON II study. If we reconsider the PRISON II results by
ncluding only patients with true CTO, the superiority of DES
ver BMS would not reach the statistical significance at 3-year
ollow-up.
At multivariate analysis we found that DES, stenosis length,
nd final minimal luminal diameter were independent predic-
ors of freedom from MACE at 3-year follow-up. Prior studies
howed lesion length and final minimal luminal diameter as
ndependent predictors of MACE during the short-term
eriod in CTO treated with DES (7,20), but an extended
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1265ot surprising if we think that the benefits of DES are obtained
y reducing restenosis and consequent TLR. Long stenoses
epresent complex lesions and involve high-risk procedures.
he extension of the disease increases the possibility of sites of
ncomplete stent expansion, increasing the risk for restenosis
nd re-intervention. Final minimal lumen diameter and resid-
al stenosis are influenced by many factors that might provoke
nadequate stent expansion (21): vessel resistance, stent dimen-
ions, delivery pressure inflations, stent recoil, and use of
oncompliant balloons. Small final minimal lumen diameters
nd high residual stenosis percentage might contribute to
estenosis and consequent TLR. The finding that BMS had an
ncreased frequency of events for all lesion lengths, final
inimal luminal diameters, and residual stenosis percentage
uggests that DES should always be preferred when lesion
ength is long, final minimal lumen diameter is expected to be
mall, or residual stenosis percentage is supposed to be high.
tudy limitations. Our report presents some limitations. First,
he study was not randomized: operator selection and inclusion
riteria might have influenced the final results. Second,
ollow-up coronary angiography was not routinely performed
ut only in patients with evidence of spontaneous or inducible
schemia. Third, the sample size was relatively small, and
lthough we found no differences in the rates of death,
yocardial infarction, or stent thrombosis, the study did not
ave sufficient power to show a difference in these clinical
vents. Fourth, data about adjunctive medical therapy were not
ollected. Finally, the analysis of only successful cases could
ias results. Despite these limitations, our study describes a
eal-world cohort of patients that had never been analyzed
efore. However, a randomized study with a larger cohort of
atients is required.
onclusions
he implantation of DES should be considered the preferred
reatment strategy for patients with CTO undergoing PCI,
ecause their benefits with regard to MACE are maintained
uring 3-year follow-up through a reduction of TLR.
eprint requests and correspondence: Dr. Francesco De Felice,
O Cardiologia Interventistica, Azienda Ospedaliera S. Camillo
orlanini, C.ne Gianicolense n 87, 00152 Rome, Italy. E-mail:
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